A Study of Zasocitinib in Adults With Nonsegmental Vitiligo (NCT07108283)
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
🩺 Plain-English Summary (8th-Grade Level)
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental form of vitiligo, similar patches occur on both sides of the body (symmetrical patches). The main aim of this study is to learn how safe zasocitinib is, how well it works and how well it is tolerated by adults with nonsegmental vitiligo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 1 year (52 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. Participants who receive placebo at the beginning will change to zasocitinib after about 6 months. During the study, participants will visit their study clinic 11 times.
Who can join: Review the eligibility criteria below.
Location: Dermatology Trial Associates — Bryant, Arkansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- Dermatology Trial Associates — Bryant, Arkansas
- First OC Dermatology — Fountain Valley, California
- Center for Dermatology Clinical Research, Inc. — Fremont, California
- The Vitiligo & Pigmentation Institute of Southern California — Los Angeles, California
- UC Davis Department of Dermatology — Sacramento, California
- Therapeutics Clinical Research — San Diego, California
- Encore Medical Research of Boynton Beach LLC. — Boynton Beach, Florida
- San Marcus Research Clinic, Inc. — Miami Lakes, Florida
- Advanced Clinical Research Institute (ACRI) — Tampa, Florida
- Encore Medical Research of Weston LLC — Weston, Florida
- DelRicht Research - Dermatology — Baton Rouge, Louisiana
- DelRicht Research (Audubon Dermatology) — New Orleans, Louisiana
- Lawrence J Green LLC — Rockville, Maryland
- Hamzavi Dermatology - Canton — Canton, Michigan
- Mount Sinai — New York, New York
- Weill Cornell Medicine — New York, New York
- Markowitz Medical dba Optiskin — New York, New York
- Bexley Dermatology (legal entity - Dermatologists of Southwestern Ohio, LLC) — Bexley, Ohio
- Medical University of South Carolina — Charleston, South Carolina
- UT Health Science Center Houston — Bellaire, Texas
- ACRC Trials — Plano, Texas
- Progressive Clinical Research-San Antonio — San Antonio, Texas
- Texas Dermatology and Laser Specialists — San Antonio, Texas
- Brunswick Dermatology Center (BDC) — Fredericton, New Brunswick
- SimcoDerm Medical and Surgical Dermatology Centre — Barrie, Ontario
📞 Contact the Study Coordinator
Phone: (877) 825-3327
Email: medinfoUS@takeda.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Nonsegmental Vitiligo
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) — Hoover, Alabama
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Birmingham, Alabama
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo — Birmingham, Alabama
Explore by condition: All Nonsegmental Vitiligo clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.